Pharmacology · Short notes

Pharmacogenomics: Short Notes & Cheat Sheet

Pharmacology and Therapeutics (IB): genes, alleles and polymorphisms, CYP450 metaboliser types, key gene–drug pairs from the FDA pharmacogenetic table, gene therapy, CRISPR and the ethics of genetic testing.

Short notes

Read these before you attempt the topic's MCQs.

CYP metaboliser phenotypes

enzyme activityPoorLittle or no activityIntermediateReducedNormalExpected responseUltrarapidExtra gene copies
The same dose gives very different levels across phenotypes; the direction of harm depends on whether the drug is a prodrug.

Basic terms

  • A pharmacogene is a gene that affects drug response; an allele is one version of it. Genotype is the gene pair a person carries; phenotype is the observable effect, such as how fast a drug is cleared.
  • A genetic polymorphism is a variant present in more than 1% of a population; most are single nucleotide polymorphisms (SNPs).
  • Pharmacogenetics studies single genes; pharmacogenomics studies the whole genome's influence on drug response.
  • CYP phenotypes: poor, intermediate, normal (extensive) and ultrarapid metabolisers.

Key gene–drug pairs

  • CYP2D6: codeine is converted to morphine. Poor metabolisers get little pain relief; ultrarapid metabolisers can get toxic morphine levels, which has killed children and breastfed infants.
  • CYP2C19: clopidogrel is a prodrug, so poor metabolisers get less antiplatelet effect.
  • CYP2C9 and VKORC1 variants change the warfarin dose needed.
  • TPMT and NUDT15 deficiency: severe bone marrow toxicity from azathioprine and mercaptopurine. DPYD deficiency: fatal toxicity from 5-fluorouracil and capecitabine.
  • HLA-B*57:01: abacavir hypersensitivity, so test before starting. HLA-B*15:02: carbamazepine SJS/TEN, mainly in people of Asian ancestry. HLA-B*58:01: allopurinol SJS.
  • G6PD deficiency: haemolysis with primaquine, dapsone and rasburicase. Slow NAT2 acetylators: isoniazid neuropathy and drug-induced lupus. UGT1A1*28: irinotecan neutropenia. SLCO1B1: simvastatin myopathy.

Clinical use

  • Personalised (precision) medicine uses genetic and clinical data to choose the drug and dose, predict response and avoid adverse reactions.
  • The FDA Table of Pharmacogenetic Associations lists gene–drug pairs where data support changing therapy or monitoring.
  • Targeted therapies depend on a tumour's genes: trastuzumab for HER2-positive breast cancer, imatinib for BCR-ABL leukaemia.
  • Genetic mechanisms also explain antibiotic resistance genes and help guide antimicrobial choice.

Gene therapy, editing and ethics

  • Gene therapy adds a working gene, often with viral vectors such as adeno-associated virus (AAV) or lentivirus.
  • CRISPR-Cas9 cuts DNA at a guided site so a gene can be disabled or corrected. The first CRISPR medicine, approved in 2023, treats sickle cell disease and β-thalassaemia.
  • Ethical issues: informed consent for testing, privacy of genetic data, discrimination, unequal access, and incidental findings.

Cheat sheet

High-yield facts in one place. Cover the right-hand column and test yourself.

Gene → drug → risk

GeneDrug · consequence
CYP2D6 ultrarapidCodeine · morphine toxicity
CYP2C19 poorClopidogrel · reduced effect
CYP2C9 / VKORC1Warfarin · dose change
TPMT / NUDT15Azathioprine · myelosuppression
DPYD5-FU, capecitabine · severe toxicity
HLA-B*57:01Abacavir · hypersensitivity
HLA-B*15:02Carbamazepine · SJS/TEN
G6PDPrimaquine, dapsone · haemolysis

Metaboliser type → effect on a prodrug vs an active drug

PhenotypeProdrug · active drug
PoorToo little effect · toxicity
NormalExpected · expected
UltrarapidToxicity · too little effect

Memory aids

Pro-drug flips the rule
Poor metabolisers accumulate active drugs (toxicity) but fail to activate prodrugs (no effect); ultrarapid metabolisers do the reverse.

Exam traps

  • A poor metaboliser of a prodrug such as clopidogrel or codeine gets less effect, not more toxicity.
  • Genotype is the genetic code; phenotype is how the person actually handles the drug.
  • HLA-B*15:02 testing before carbamazepine matters most in people of Asian ancestry.
  • A polymorphism must occur in more than 1% of the population; rarer variants are mutations.

Revised? Now test yourself.

Attempt the Pharmacogenomics MCQs while the notes are fresh. Anything you get wrong is saved to your incorrect list for the next revision round.

More Pharmacology notes